Drug research

Donidalorsen

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as IONIS-PKK-LRx; ISIS 721744

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Donidalorsen Treatment in Children With Hereditary AngioedemaNCT07298447	IONS	Phase 3	Recruiting	2029-06Estimated
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)NCT05392114	IONS	Phase 3	Active not recruiting	2026-12Estimated
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaNCT04307381	IONS	Phase 2	Completed	2025-01-24Actual
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)NCT05139810	IONS	Phase 3	Completed	2023-11-09Actual

IONSRecruitingPrimary completion: 2029-06 · Estimated

Trial details

IONSActive not recruitingPrimary completion: 2026-12 · Estimated

Trial details

IONSCompletedPrimary completion: 2025-01-24 · Actual

Trial details

IONSCompletedPrimary completion: 2023-11-09 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.